Psoríase que tem como causa uma mutação no gene IL36RN.
Introdução
O que você precisa saber de cara
Psoríase que tem como causa uma mutação no gene IL36RN.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 9 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 15 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
2 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive.
Subunit of clathrin-associated adaptor protein complex 1 that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes. The AP complexes mediate both the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules. Involved in TLR3 trafficking (PubMed:24791904)
Golgi apparatusCytoplasmic vesicle membraneMembrane, clathrin-coated pit
Psoriasis 15, pustular
A form of pustular psoriasis, a life-threatening disease defined by repeated flares of sudden onset consisting of diffuse erythematous skin eruption characterized by rapid coverage with pustules, high-grade fever, asthenia, marked leukocytosis, and elevated serum levels of C-reactive protein.
Inhibits the activity of interleukin-36 (IL36A,IL36B and IL36G) by binding to receptor IL1RL2 and preventing its association with the coreceptor IL1RAP for signaling. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response; similar to the IL-1 system with which it shares the coreceptor. Proposed to play a role in skin inflammation. May be involved in the innate immune response to fungal pathogens, such as Aspergillus
CytoplasmSecreted
Psoriasis 14, pustular
A life-threatening disease defined by repeated flares of sudden onset consisting of diffuse erythematous skin eruption characterized by rapid coverage with pustules, high-grade fever, asthenia, marked leukocytosis, and elevated serum levels of C-reactive protein.
Medicamentos e terapias
Mecanismo: Interleukin-23 inhibitor
Mecanismo: Interleukin-23 inhibitor
Mecanismo: IL36 receptor antagonist
Mecanismo: TNF-alpha inhibitor
Mecanismo: IL36 receptor antagonist
Mecanismo: TNF-alpha inhibitor
Variantes genéticas (ClinVar)
67 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
5 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Acrodermatite contínua de Hallopeau
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Pesquisa e ensaios clínicos
3 ensaios clínicos encontrados.
Publicações mais relevantes
Case Report: Periungual Xeligekimab injection for refractory Acrodermatitis continua of Hallopeau.
This case report presents the novel and successful use of periungual Xeligekimab injections for managing refractory Acrodermatitis Continua of Hallopeau (ACH), representing the first documented application of this localized administration route for the IL-17A inhibitor. It contributes to the scientific literature by demonstrating a promising alternative therapeutic strategy for treatment-resistant ACH, highlighting the potential for enhanced local efficacy and minimized systemic exposure. The patient was a 36-year-old woman with a two-decade history of ACH affecting her digits, characterized by persistent periungual and subungual erythema, sterile pustules, significant nail plate dystrophy with thickening and fragmentation, and associated digital swelling, tenderness, and restricted motion. Prior therapies, including topical corticosteroids, phototherapy, and systemic tofacitinib, had proven ineffective. Diagnosis was confirmed clinically and supported by MRI, which revealed active bone marrow edema in the distal phalanges. The therapeutic intervention involved initial periungual injections of a diluted Xeligekimab formulation, which led to partial improvement. This was followed by a series of injections using undiluted Xeligekimab (100 mg/mL). This escalation resulted in marked clinical resolution: complete clearance of pustules and inflammation, healthy nail regrowth, and resolution of digital swelling and pain. Concurrently, the Dermatology Life Quality Index and pain scores dramatically improved, and follow-up MRI showed substantial resolution of the underlying bone marrow edema, confirming the treatment's efficacy on both cutaneous and deep osseous inflammation.
Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab.
Acrodermatitis continua of Hallopeau (ACH) is a rare, localized variant of pustular psoriasis that primarily affects the distal digits and nail apparatus, often presenting with recurrent pustules, nail dystrophy, and significant functional impairment. Due to its rarity and chronic relapsing course, ACH is notoriously difficult to treat, and standardized treatment guidelines are lacking. We present the case of a 67-year-old male with ACH who failed multiple therapies, including corticosteroids, topical tapinarof, and oral deucravacitinib, before achieving rapid and sustained improvement with bimekizumab, a monoclonal antibody targeting interleukin-17A and IL-17F. Within one month of initiating bimekizumab, the patient experienced marked clinical improvement in both skin lesions and joint pain, with continued progress allowing him to return to work. This case highlights the potential utility of dual IL-17A/F inhibition in neutrophil-dominant pustular conditions such as ACH. As more case reports document favorable outcomes, bimekizumab may emerge as a valuable treatment option for patients with refractory ACH, offering targeted cytokine blockade in a condition with few effective therapies.  .
Clinical Features and Long-Term Outcomes in 109 Pediatric Generalized Pustular Psoriasis.
Pediatric-onset generalized pustular psoriasis (PGPP) is a rare inflammatory disorder characterized by recurrent flares and challenging management. This study aimed to review the clinical features, flare patterns, and treatment options. We analyzed PGPP patients diagnosed at Beijing Children's Hospital from 2006 to 2023 who had complete medical record. Data on clinical characteristics, flare numbers, and flare duration were collected through medical record and telephone survey. The flare frequency was calculated by dividing the flare numbers by the years in each age range. Flare duration was categorized as ≤4 weeks or >4 weeks. In addition, we investigated the factors associated with flare frequency in PGPP patients. A total of 109 patients with PGPP were included in the study, with a follow-up duration ranging from 1.90 to 22.80 years. The median age of onset was 6.00 years, with a higher prevalence in males (73, 66.97%). Most patients (55, 50.46%) experienced their first flare between the ages of 7 and 12 years. A total of 45 patients (41.28%) had history of psoriasis vulgaris, 16 (14.68%) had history of acrodermatitis continua of Hallopeau, and 4 (3.67%) had history of psoriatic arthritis. Respiratory infection was the most common trigger, affecting 35 patients (32.11% of cases). The annual flare frequency was 0.68. The frequency and duration of flares showed a decreasing trend with increasing age. Earlier onset age is associated with a higher flare frequency. Before 2020, conventional therapies were most commonly used, with acitretin used in 67 patients (61.47%). Following 2020, secukinumab became the most often used medication (44 patients, 40.37%). PGPP exhibits a trend toward flare decrease with age, yet recurrence remains common. Earlier onset age may be associated with higher flare frequency. At present, biologic agents are the main treatment. These findings provide new insights into PGPP.
Response to Han et al., "Comment on Iorizzo's acrodermatitis continua of Hallopeau-clinical review and proposed management algorithm".
Comment on Iorizzo et al, "Acrodermatitis continua of Hallopeau-clinical review and proposed management algorithm".
Publicações recentes
Case Report: Periungual Xeligekimab injection for refractory Acrodermatitis continua of Hallopeau.
Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab.
Clinical phenotype of 504 pustular psoriasis patients from Europe and Egypt: a multi-center observational study.
📚 EuropePMC176 artigos no totalmostrando 156
Case Report: Periungual Xeligekimab injection for refractory Acrodermatitis continua of Hallopeau.
Frontiers in immunologyDual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab.
Journal of drugs in dermatology : JDDClinical phenotype of 504 pustular psoriasis patients from Europe and Egypt: a multi-center observational study.
Clinical and experimental dermatologyLong-term control of refractory acrodermatitis continua of Hallopeau with subcutaneous spesolimab: A case report.
JAAD case reportsClinical Features and Long-Term Outcomes in 109 Pediatric Generalized Pustular Psoriasis.
Dermatology (Basel, Switzerland)Rapid Resolution of Pediatric Acrodermatitis Continua of Hallopeau With Spesolimab.
PediatricsSuccessful treatment of severe acrodermatitis continua of Hallopeau with guselkumab.
Dermatology online journalVunakizumab for Treatment of Acrodermatitis Continua of Hallopeau: A Case Report and Literature Review.
Psoriasis (Auckland, N.Z.)Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies.
Frontiers in immunologyRefractory Acrodermatitis Continua of Hallopeau in a Pediatric Patient: Unveiling Underlying Mixed Connective Tissue Disorder.
The Journal of clinical and aesthetic dermatologyAcrodermatitis continua of Hallopeau-clinical review and proposed management algorithm.
Journal of the American Academy of DermatologySpesolimab in generalized pustular psoriasis complicated by acrodermatitis continua of Hallopeau: a case report and mechanistic insights.
Frontiers in immunologyApremilast Coadministered with Secukinumab for Effective Treatment of Acrodermatitis Continua of Hallopeau: A Case Report.
Clinical, cosmetic and investigational dermatologyEpidemiological, Genetic, Clinical, and Treatment Differences of Generalized Pustular Psoriasis and Acrodermatitis Continua of Hallopeau Across Ethnicities: A Systematic Review.
American journal of clinical dermatologyAcrodermatitis Continua of Hallopeau and Generalised Pustular Psoriasis: Case Reports of Two Different Manifestations of IL36RN Mutation in Siblings.
Psoriasis (Auckland, N.Z.)Acrodermatitis continua of Hallopeau successfully treated with spesolimab.
Annales de dermatologie et de venereologieExpanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases.
The Journal of dermatological treatmentCase report: Successful treatment with spesolimab of acrodermatitis continua of Hallopeau in an older patient without IL36RN mutations.
Frontiers in immunologySuccessful treatment of severe acrodermatitis continua of hallopeau with Bimekizumab: A case report.
SAGE open medical case reportsA rare severe acrodermatitis continua of Hallopeau treated with spesolimab.
The Journal of dermatologySpesolimab in refractory paediatric acrodermatitis continua of Hallopeau, a case series.
Journal of the European Academy of Dermatology and Venereology : JEADVAcrodermatitis Continua of Hallopeau Successfully Treated With Bimekizumab.
Dermatology practical & conceptualAcrodermatitis continua of hallopeau: aggravating factors and treatment outcomes of 96 patients.
The Journal of dermatological treatmentIs tofacitinib monotherapy also effective for the treatment of Acrodermatitis continua of Hallopeau?
The Australasian journal of dermatologySquamous cell carcinoma developing from acrodermatitis continua of Hallopeau in a patient with deficiency of interleukin-36-receptor antagonist.
Italian journal of dermatology and venereologyRefractory acrodermatitis continua of Hallopeau successfully treated by baricitinib: A case report.
The Journal of dermatologyRapid improvement in refractory acrodermatitis continua of Hallopeau with spesolimab injection.
Clinical and experimental dermatologyAcrodermatitis Continua of Hallopeau Evolving into Psoriatic Monoarthritis: Successfully Treated with Apremilast.
SkinmedSuccessful treatment of acrodermatitis continua of Hallopeau coexisting with flexural psoriasis with upadacitinib: a case report.
Clinical and experimental dermatologyLong-term treatment with risankizumab of palmoplantar pustulosis and acrodermatitis continua of hallopeau.
Italian journal of dermatology and venereologyEffective management of acrodermatitis continua of Hallopeau with guselkumab in a Wiskott-Aldrich syndrome patient.
International journal of dermatologyPlaque psoriasis, generalized pustular psoriasis, palmoplantar pustulosis, and acrodermatitis continua of Hallopeau successfully treated with bimekizumab: a promising therapeutic approach.
European journal of dermatology : EJDTargeted therapy outcomes in acrodermatitis continua of Hallopeau: A systematic review.
Journal of biomedical researchReflectance confocal microscopy and dermoscopic features of acrodermatitis continua of Hallopeau.
International journal of dermatologyAcrodermatitis continua of Hallopeau upon PD-L1 therapy for metastatic urothelial carcinoma.
European journal of dermatology : EJDGeneralized acrodermatitis continua of Hallopeau with an IL36RN variant successfully treated with bimekizumab.
The Journal of dermatologyGenetic analysis of different subtypes of aseptic pustulosis in the Chinese population.
Clinical and experimental dermatologyA retrospective analysis of 65 patients with acrodermatitis continua of Hallopeau.
Experimental dermatologyAcquired diffuse palmoplantar erythema with keratoderma in Chinese patients with pustular psoriasis: A predictor for IL36 receptor antagonist c.115+6T>C mutation?
Experimental dermatologySuccessful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report.
Frontiers in immunologySpesolimab Response in a Girl With Acrodermatitis Continua of Hallopeau.
JAMA dermatologySuccessful treatment of acrodermatitis continua of Hallopeau by TYK2 inhibitor with every other day.
The Journal of dermatological treatmentLow grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled.
Frontiers in medicineLocal injection of micro-dose guselkumab for acrodermatitis continua of Hallopeau after failure of systemic ixekizumab treatment.
International journal of dermatologyAutoinflammatory Keratinization Diseases-The Concept, Pathophysiology, and Clinical Implications.
Clinical reviews in allergy & immunologyTreatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab.
JAMA dermatologyPaediatric acrodermatitis continua of Hallopeau: perspectives of a patient and their mother.
Clinical and experimental dermatologyAnti-Interleukin-17s for successful management of pustular psoriasis.
CytokineAcrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib.
European journal of dermatology : EJDAcrodermatitis continua of Hallopeau in an elderly patient successfully and rapidly treated with risankizumab: a case report.
The Journal of dermatological treatmentSuccessful treatment of acrodermatitis continua of Hallopeau with tildrakizumab: A case report.
SAGE open medical case reportsPustular psoriasis: A distinct aetiopathogenic and clinical entity.
Indian journal of dermatology, venereology and leprologyIxekizumab for the Treatment of Acrodermatitis Continua of Hallopeau and Inverse Psoriasis.
Indian journal of dermatologyBiologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab.
Dermatology practical & conceptualAdalimumab treatment for acrodermatitis continua of Hallopeau: three cases refractory to IL-17 inhibition.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGDermoscopy of Acrodermatitis Continua of Hallopeau.
Indian dermatology online journalAcrodermatitis continua of Hallopeau and generalised pustular psoriasis: Should they be the same or different entities?
Experimental dermatologyAcrodermatitis Continua of Hallopeau Successfully Treated with Ustekinumab: A Case Report and Literature Review.
Clinical, cosmetic and investigational dermatologyAcrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report.
SAGE open medical case reportsSquamous cell carcinoma mimicking acrodermatitis continua suppurativa in a patient with generalized pustular psoriasis.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGDeficiency of interleukin-36 receptor antagonist (DITRA): An analysis of 58 Chinese patients in a tertiary hospital in Taiwan.
Experimental dermatologyRapid and sustained response to apremilast in a patient with long-standing acrodermatitis continua of Hallopeau.
Dermatology online journalAcrodermatitis Continua of Hallopeau: A Diagnostic Challenge.
Indian dermatology online journalDifferent Clinical Features of Pediatric Generalized Pustular Psoriasis in Patients with or without IL36RN Variants.
Dermatology (Basel, Switzerland)Acute Generalized Pustular Psoriasis Developed Resistance to Adalimumab Was Successfully Treated with Narrowband Ultraviolet B and Acitretin: A Case Report.
Clinical, cosmetic and investigational dermatologyA rare case of Acrodermatitis continua of Hallopeau successfully treated with topical calcipotriol/betamethasone dipropionate ointment associated with Jaccaud's arthropathy: A case report.
SAGE open medical case reportsEpidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020.
The Journal of dermatologyTargeting IL-17A for the treatment of pustular psoriasis: a comprehensive review.
Expert opinion on biological therapyClinical Characteristics of Patients with Pustular Psoriasis: A Single-Center Retrospective Observational Study.
VaccinesLine-field confocal optical coherence tomography: a new tool for non-invasive differential diagnosis of pustular skin disorders.
Journal of the European Academy of Dermatology and Venereology : JEADVA case of acrodermatitis continua of Hallopeau successfully treated with guselkumab.
Dermatologic therapyCertolizumab Pegol: A New Therapeutic Approach for Acrodermatitis Continua of Hallopeau.
Skin appendage disordersAcrodermatitis continua of Hallopeau: historical perspectives and modern management.
Italian journal of dermatology and venereologyPalmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort.
Journal of the European Academy of Dermatology and Venereology : JEADVAcrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?
Dermatologic therapyA case of acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis successfully treated with guselkumab.
International journal of dermatologyAcrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report.
Dermatologic therapyClinico-Pathological and Dermoscopic Features in Acrodermatitis Continua of Hallopeau.
Indian journal of dermatologyPustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets.
Journal of dermatological sciencePustular Psoriasis: From Pathophysiology to Treatment.
BiomedicinesTreatment and molecular profiling of acrodermatitis continua of Hallopeau during pregnancy using targeted therapy.
JAAD case reportsPustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Dermatology and therapySuccessful therapy of acrodermatitis continua of Hallopeau with IL-23 blockers -two new cases.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGTreating paediatric acrodermatitis continua of Hallopeau with adalimumab: a case series.
Clinical and experimental dermatologyEpidemiology and clinical features of pustular psoriasis: A 15-year retrospective cohort.
The Journal of dermatologyCOVID-19 and exacerbation of dermatological diseases: A review of the available literature.
Dermatologic therapyClinical background of patients with psoriasiform skin lesions due to tumor necrosis factor antagonist administration at a single center.
The Journal of dermatologySuccessful Treatment of Acrodermatitis Continua of Hallopeau with an Anti-IL-17A Agent.
Indian journal of dermatologyPustular Psoriasis and Associated Musculoskeletal Disorders.
The Journal of rheumatology. SupplementAcrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin.
Biologics : targets & therapyInhibition of Progression of Acrodermatitis Continua of Hallopeau With Baricitinib.
JAMA dermatologySquamous cell carcinoma arising on acrodermatitis continua of Hallopeau: clinical and noninvasive skin imaging features.
International journal of dermatologyA brief guide to pustular psoriasis for primary care providers.
Postgraduate medicine[Acrodermatitis continua of Hallopeau and psoriatic arthritis: A case report].
MedwaveBrodalumab in the treatment of recalcitrant acrodermatitis continua of Hallopeau.
Dermatologic therapyThree cases of IL36RN-associated pustulosis: An evolution of acrodermatitis continua of Hallopeau to generalized pustular psoriasis.
Indian journal of dermatology, venereology and leprologyVisual Dermatology: Acrodermatitis Continua of Hallopeau.
Journal of cutaneous medicine and surgeryEtanercept for pediatric acrodermatitis continua of Hallopeau: A case report and literature review.
Dermatologic therapyTreatment of acrodermatitis continua of Hallopeau: A case series of 39 patients.
The Journal of dermatologyBiologics in the treatment of pustular psoriasis.
Expert opinion on drug safetyClinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: A retrospective analysis of 66 cases in a single center in Taiwan.
The Journal of dermatologyIntramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: An alternative in COVID-19.
Dermatologic therapyA case of pediatric acrodermatitis continua of Hallopeau successfully treated with adalimumab biosimilar.
Dermatologic therapySpesolimab: A Novel Treatment for Pustular Psoriasis.
Journal of cutaneous medicine and surgeryEfficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau.
Journal of the European Academy of Dermatology and Venereology : JEADVPustular Psoriasis: The Dawn of a New Era.
Acta dermato-venereologicaEffectiveness of brodalumab in acrodermatitis continua of Hallopeau: A case report.
Dermatologic therapyImage Gallery: Pemphigus vulgaris mimicking acrodermatitis continua of Hallopeau.
The British journal of dermatologyTreatment of Recalcitrant Acrodermatitis Continua of Hallopeau With Brodalumab.
Journal of drugs in dermatology : JDDAcrodermatitis continua of Hallopeau: clinical perspectives.
Psoriasis (Auckland, N.Z.)Case Report: Paradoxical acrodermatitis of Hallopeau-like eruption following anti-IL-17 therapy.
F1000ResearchCrusted scabies mimicking an acrodermatitis continua of Hallopeau.
Boletin medico del Hospital Infantil de MexicoOutcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau.
Biologics : targets & therapyTreatment of acrodermatitis continua of hallopeau with ixekizumab.
The Journal of dermatological treatmentSuccessful treatment of acrodermatitis continua of Hallopeau with apremilast.
The Journal of dermatologyNails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
Dermatologic therapyBiologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature.
Dermatologic therapyThe Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.
Journal of cutaneous medicine and surgeryAcrodermatitis Continua of Hallopeau with Psoriatic Arthritis.
The Journal of rheumatologyAcrodermatitis continua of Hallopeau response to optimized biological therapy.
Dermatology online journalAcrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report.
SAGE open medical case reportsApremilast as a new treatment option for Acrodermatitis continua of Hallopeau.
The Australasian journal of dermatologyAcrodermatitis continua of Hallopeau with dense infiltration of IgG4-positive cells in the lesional dermis.
The British journal of dermatologyAcrodermatitis Continua of Hallopeau.
JAMA dermatologyAcrodermatitis continua of Hallopeau successfully treated with secukinumab.
The Journal of dermatological treatmentRecalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.
JAAD case reportsClinical and genetic differences between pustular psoriasis subtypes.
The Journal of allergy and clinical immunologyA case of acrodermatitis continua of Hallopeau (ACH) successfully treated with sulfasalazine.
Dermatologic therapyAcrodermatitis continua of Hallopeau and geographic tongue are variants of pustular psoriasis.
JAAD case reportsTreatment of acrodermatitis continua of Hallopeau with ustekinumab as monotherapy after failure of anti-TNF agents.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGGeneralized pustular psoriasis: a review and update on treatment.
Journal of the European Academy of Dermatology and Venereology : JEADVAcrodermatitis Continua of Hallopeau with Bone Resorption in an 8-Year-Old Patient: A Case Report.
Case reports in dermatologyPustular psoriasis and related pustular skin diseases.
The British journal of dermatologyHighly Resistant Acrodermatitis Continua of Hallopeau and Pustular Psoriasis.
Skin appendage disordersEfficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review.
The Journal of dermatological treatmentThe genetic basis for most patients with pustular skin disease remains elusive.
The British journal of dermatologyDermoscopy in facilitating the recognition of acrodermatitis continua of Hallopeau.
The Journal of dermatologyEuropean consensus statement on phenotypes of pustular psoriasis.
Journal of the European Academy of Dermatology and Venereology : JEADVA Painful Periungual Red Spot in a Patient with Onychodystrophy.
Skin appendage disordersShort- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report.
Journal of cutaneous medicine and surgeryAcrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab.
JAAD case reportsRefractory acrodermatitis continua of Hallopeau successfully treated with oral alitretinoin.
The Journal of dermatologyUstekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents.
Dermatologic therapyNovel Application of High-Dose-Rate Brachytherapy for Severe, Recalcitrant Acrodermatitis Continua of Hallopeau.
JAMA dermatologySecukinumab for Acrodermatitis Continua of Hallopeau.
JAMA dermatologySpeckled variance optical coherence tomography for the assessment of nail involvement in acrodermatitis continua of Hallopeau: A case study.
The Journal of international medical researchPustular psoriasis: pathophysiology and current treatment perspectives.
Psoriasis (Auckland, N.Z.)Acrodermatitis Continua of Hallopeau with Granuloma-like Vegetation, Osteolysis and IL36RN Mutation.
Acta dermato-venereologicaIL36RN Mutations Affect Protein Expression and Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases.
The Journal of investigative dermatologyPustular Psoriasis of Pregnancy with Acrodermatitis Continua of Hallopeau.
Indian journal of dermatologyA Case of Acrodermatitis Continua of Hallopeau Following Chronic Pustular Cheilitis.
Dermatology and therapy[A man with a painful index finger].
Nederlands tijdschrift voor geneeskundeCorrelation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients.
Archives of dermatological researchTreatment of Acrodermatitis Continua of Hallopeau With Ustekinumab as Monotherapy.
JAMA dermatologyIloprost administration in acrodermatitis of Hallopeau complicated by acquired toes syndactyly: a case report and review of the literature.
European review for medical and pharmacological sciencesSuccessful treatment of Acrodermatitis continua of Hallopeau associated with psoriatic arthritis with adalimumab.
European journal of rheumatologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Acrodermatite contínua de Hallopeau.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Acrodermatite contínua de Hallopeau
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Case Report: Periungual Xeligekimab injection for refractory Acrodermatitis continua of Hallopeau.
- Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab.
- Clinical Features and Long-Term Outcomes in 109 Pediatric Generalized Pustular Psoriasis.
- Response to Han et al., "Comment on Iorizzo's acrodermatitis continua of Hallopeau-clinical review and proposed management algorithm".
- Comment on Iorizzo et al, "Acrodermatitis continua of Hallopeau-clinical review and proposed management algorithm".
- Clinical phenotype of 504 pustular psoriasis patients from Europe and Egypt: a multi-center observational study.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:163931(Orphanet)
- OMIM OMIM:614204(OMIM)
- MONDO:0013626(MONDO)
- GARD:17679(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Q1947290(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
